文献速递前列腺癌

根治性前列腺切除术后持续PSA升高的管理:系统综述

Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature.
PubMed 文献 · Eur Urol Oncol · 2021-02-08

该系统综述筛选了2374篇文章,最终纳入25项研究共5217例根治性前列腺切除术后PSA持续可检测的男性患者,评估肿瘤学结局与挽救治疗的效果。结果显示PSA持续(最常定义为>0.1 ng/ml)与更差的肿瘤学结局显著相关,挽救性放疗±雄激素剥夺治疗与生存改善相关,但现有证据级别较低且缺乏随机对照试验。

要点

  • 术后6-8周PSA持续>0.1 ng/ml与疾病侵袭性及更差肿瘤学结局显著相关。
  • 挽救性放疗±雄激素剥夺治疗与生存改善相关,但证据级别仍低。
  • 基于病理特征、PSA水平/动力学和基因组分类器的风险分层有助于个体化治疗。

核心结论

  • 根治性前列腺切除术后PSA持续与不良肿瘤学结局强相关。
  • 本综述提示立即放疗可能获益,但当前证据级别仍低。
  • 后续治疗指征应基于个体化讨论,综合考虑所有预后因素及拟议治疗的疗效/毒性平衡。

研究设计与样本

  • 系统综述于2020年5月实施,遵循PRISMA指南。
  • 共筛选2374篇文章,纳入25项研究、5217例男性患者。

主要发现

  • PSA持续最常定义为PSA>0.1 ng/ml。
  • PSA持续与疾病侵袭性显著相关,且肿瘤学结局差于PSA不可测者。
  • 5年无复发生存率范围为21.5%至67.0%。
  • ≥10年癌症特异性生存率为75-88%。
  • 挽救性放疗±雄激素剥夺治疗与生存结局改善相关。

关键数值与推荐

  • PSA持续最常定义为PSA>0.1 ng/ml。
  • 5年无复发生存率范围21.5%-67.0%。
  • ≥10年癌症特异性生存率75%-88%。

临床怎么用

  • 术后PSA持续患者应考虑立即放疗以改善生存结局。
  • 治疗决策应基于病理特征、PSA水平/动力学和基因组分类器进行风险分层个体化讨论。
  • 分子影像在该场景中的价值尚待进一步评估。

局限性

  • 纳入研究多为回顾性设计。
  • 缺乏针对该特定人群的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The prognosis and optimal management of pN0/pN1 patients with persistently elevated prostate-specific antigen (PSA) 6-8 wk after radical prostatectomy (RP) remain unclear. OBJECTIVE: To perform a systematic review of oncologic outcomes and effectiveness of salvage therapies in men with a detectable PSA level after RP. EVIDENCE ACQUISITION: A systematic review was performed in May 2020. A total of 2374 articles were screened, and 25 studies including 5217 men were selected and included in the systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. EVIDENCE SYNTHESIS: PSA persistence was most commonly defined as PSA >0.1 ng/ml. PSA persistence was significantly correlated with disease aggressiveness and associated with worse oncologic outcomes than in men with undetectable PSA levels. The 5-yr recurrence-free survival rates varied from 21.5% to 67.0%. The ≥10-yr cancer-specific survival was 75-88%. Salvage radiotherapy ± androgen deprivation therapy was associated with improved survival outcomes. Risk stratification according to pathologic features, PSA levels/kinetics, and genomic classifier may aid in personalization of treatment. The usefulness of molecular imaging in this setting remains underevaluated. Main limitations of this systematic review are the retrospective design of the included studies and the lack of randomized controlled trials (RCTs) focusing on this specific population. CONCLUSIONS: PSA persistence after RP is strongly correlated with poor oncologic outcomes. Our review suggests a benefit from immediate radiotherapy; however, current evidence is still low. Indication of subsequent therapies should be based on individual discussions, taking into account all the prognostic factors and the efficacy/toxicity imbalance of proposed treatment. Results from ongoing RCTs are awaited to state on the role of more intensified systemic therapy in this population. PATIENT SUMMARY: Patients with a detectable prostate-specific antigen level after surgery are at high risk of subsequent progression. Immediate radiotherapy might improve survival outcomes. Further research into the role of molecular imaging and genomic classifier is needed in this patient population.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ploussard G, Fossati N, Wiegel T, et al. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021. PMID: 33574012. doi:10.1016/j.euo.2021.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。